Accolade Statistics
Total Valuation
Bone Biologics has a market cap or net worth of $4.38 million. The enterprise value is $1.64 million.
Important Dates
The next estimated earnings date is Friday, August 8, 2025, after market close.
| Earnings Date | Aug 8, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Bone Biologics has 1.61 million shares outstanding. The number of shares has increased by 421.86% in one year.
| Current Share Class | 1.61M |
| Shares Outstanding | 1.61M |
| Shares Change (YoY) | +421.86% |
| Shares Change (QoQ) | +28.35% |
| Owned by Insiders (%) | 0.04% |
| Owned by Institutions (%) | 0.37% |
| Float | 1.45M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 0.51 |
| P/TBV Ratio | 1.51 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 12.59
| Current Ratio | 12.59 |
| Quick Ratio | 10.94 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -129.48% and return on invested capital (ROIC) is -82.64%.
| Return on Equity (ROE) | -129.48% |
| Return on Assets (ROA) | -77.73% |
| Return on Invested Capital (ROIC) | -82.64% |
| Return on Capital Employed (ROCE) | -149.58% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$3.74M |
| Employee Count | 2 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -78.94% in the last 52 weeks. The beta is 1.22, so Bone Biologics's price volatility has been higher than the market average.
| Beta (5Y) | 1.22 |
| 52-Week Price Change | -78.94% |
| 50-Day Moving Average | 4.09 |
| 200-Day Moving Average | 5.68 |
| Relative Strength Index (RSI) | 35.16 |
| Average Volume (20 Days) | 76,581 |
Short Selling Information
The latest short interest is 46,240, so 2.88% of the outstanding shares have been sold short.
| Short Interest | 46,240 |
| Short Previous Month | 521,622 |
| Short % of Shares Out | 2.88% |
| Short % of Float | 3.19% |
| Short Ratio (days to cover) | 0.03 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -4.35M |
| Pretax Income | -5.12M |
| Net Income | -7.48M |
| EBITDA | n/a |
| EBIT | -4.35M |
| Earnings Per Share (EPS) | -$20.88 |
Full Income StatementBalance Sheet
The company has $2.75 million in cash and n/a in debt, giving a net cash position of $2.75 million or $1.71 per share.
| Cash & Cash Equivalents | 2.75M |
| Total Debt | n/a |
| Net Cash | 2.75M |
| Net Cash Per Share | $1.71 |
| Equity (Book Value) | 2.91M |
| Book Value Per Share | 5.34 |
| Working Capital | 2.91M |
Full Balance SheetCash Flow
| Operating Cash Flow | -3.75M |
| Capital Expenditures | n/a |
| Free Cash Flow | -3.75M |
| FCF Per Share | -$2.33 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
